Bausch Health Companies (NYSE:BHC) was upgraded by investment analysts at ValuEngine from a “sell” rating to a “hold” rating in a research report issued on Monday.
Other research analysts have also issued reports about the stock. Zacks Investment Research lowered shares of Bausch Health Companies from a “buy” rating to a “hold” rating in a research report on Monday. Royal Bank of Canada set a $30.00 target price on shares of Bausch Health Companies and gave the stock a “hold” rating in a research report on Monday, October 8th. HC Wainwright set a $25.00 target price on shares of Bausch Health Companies and gave the stock a “hold” rating in a research report on Monday, October 15th. Piper Jaffray Companies upgraded shares of Bausch Health Companies from a “neutral” rating to an “overweight” rating and set a $27.00 target price on the stock in a research report on Tuesday, January 1st. Finally, BMO Capital Markets restated a “hold” rating and set a $26.00 target price on shares of Bausch Health Companies in a research report on Tuesday, November 13th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $26.47.
Get Bausch Health Companies alerts:
BHC traded up $0.56 on Monday, hitting $25.20. 4,869,934 shares of the company were exchanged, compared to its average volume of 4,315,497. The company has a current ratio of 1.14, a quick ratio of 0.91 and a debt-to-equity ratio of 7.55. Bausch Health Companies has a fifty-two week low of $14.44 and a fifty-two week high of $28.45. The firm has a market capitalization of $8.66 billion, a P/E ratio of 6.58, a PEG ratio of 0.32 and a beta of 0.63.
Bausch Health Companies (NYSE:BHC) last issued its earnings results on Tuesday, November 6th. The company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $0.84 by $0.31. Bausch Health Companies had a negative net margin of 40.41% and a positive return on equity of 32.19%. The company had revenue of $2.14 billion for the quarter, compared to analyst estimates of $2.09 billion. Bausch Health Companies’s revenue was down 3.7% compared to the same quarter last year. Analysts predict that Bausch Health Companies will post 3.81 EPS for the current year.
In other Bausch Health Companies news, insider Thomas Appio purchased 25,440 shares of the stock in a transaction dated Friday, December 14th. The shares were acquired at an average cost of $22.96 per share, for a total transaction of $584,102.40. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 11.54% of the stock is owned by corporate insiders.
Hedge funds have recently added to or reduced their stakes in the company. Morgan Stanley acquired a new stake in shares of Bausch Health Companies in the third quarter valued at approximately $57,631,000. Vanguard Group Inc. acquired a new stake in Bausch Health Companies during the third quarter worth approximately $223,173,000. Andra AP fonden acquired a new stake in Bausch Health Companies during the third quarter worth approximately $7,039,000. Contravisory Investment Management Inc. acquired a new stake in Bausch Health Companies during the fourth quarter worth approximately $104,000. Finally, NEXT Financial Group Inc acquired a new stake in Bausch Health Companies during the third quarter worth approximately $101,000. Institutional investors and hedge funds own 49.69% of the company’s stock.
About Bausch Health Companies
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal.
Read More: Market Capitalization – What it Means for Investors
To view ValuEngine’s full report, visit ValuEngine’s official website.